



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

**Meeting to commence at 9.30 am on Wednesday 8th December 2021
(via Zoom)**

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of the previous meeting** 1/AWMSG/1221
5. **Chairman's report**
6. **Antimicrobial Wound Dressings (AWDs) Statement, Recommendations and Guidance – for acknowledgement** 2/AWMSG/1221
7. **National Prescribing Indicator Quarterly Report to April 2021 – for information** 3/AWMSG/1221
8. **Heart Failure in Wales in 2021- A Parallel Approach – for acknowledgement** 4/AWMSG/1221 Appendix
9. **Appraisal 1: Paediatric licence extension submission Rivaroxaban (Xarelto[®]) for the treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment** 5/AWMSG/1221 Appendices
10. **Appraisal 2: Paediatric licence extension submission Dabigatran etexilate (Pradaxa[®]) for the treatment of VTE and prevention of recurrent VTE in paediatric patients from 8 years to less than 18 years of age** 6/AWMSG/1221 Appendices

To protect commercial confidentiality the following appraisal will be held in private and all observers will be asked to leave the meeting

11. **Appraisal 3: Full Submission (PAS) Cannabidiol (Epidyolex[®]) for adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older** 7/AWMSG/1221 Appendices
12. **Appraisal 4: Paediatric licence extension submission (PAS) Clostridium botulinum neurotoxin type A (Xeomin[®]) for symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological/neurodevelopmental disorders** 8/AWMSG/1221 Appendices

The outcome of all appraisals will be uploaded to the AWMSG website after the meeting.